METALLICA

STUDY TO EVALUATE THE EFFECT OF METFORMIN IN THE PREVENTION OF HYPERGLYCEMIA IN HR(+)/HER2(-) PIK3CA-MUTATED ADVANCED BREAST CANCER PATIENTS TREATED WITH ALPELISIB PLUS ENDOCRINE THERAPY

CLINICAL TRIAL DETAILS

METALLICA IS A STUDY TO EVALUATE THE EFFECT OF METFORMIN IN THE PREVENTION OF HYPERGLYCEMIA IN HR+/HER2- PIK3CA-MUTATED ADVANCED BREAST CANCER PATIENTS TREATED WITH ALPELISIB PLUS ENDOCRINE THERAPY. METALLICA IS AN OPEN-LABEL, PHASE 2 TRIAL CONDUCTED FOLLOWING A SIMON’S TWO-STAGE DESIGN, EVALUATING WHETHER PROPHYLACTIC METFORMIN BEFORE ALPELISIB PLUS ENDOCRINE TREATMENT REDUCES THE INCIDENCE AND SEVERITY OF ALPELISIB-INDUCED HYPERGLYCEMIA.

METALLICA AT CLINICALTRIALS.GOV

COUNTRY

STATUS

TUMOR TYPE

PHASE

SITES

HR+/HER2-/PIK3CA-mutated Advanced Breast Cancer

Spain

Analysis

TRIAL OVERVIEW

PRESS RELEASE

-----

SCIENTIFIC IMPACT

eClinicalMedicine (The Lancet) 2024 publication

BLOG ARTICLES RELATED

Spotlight – METALLICA hyperglycemia management in breast cancer clinical trial

TRIAL SITES

Hospital Universitario de Basurto (Spain) Complejo Hospitalario Universitario de Santiago (CHUS) (Spain) Hospital General Universitario de Alicante (Spain) Hospital Clínico Universitario Virgen de la Arrixaca (Spain) Hospital Universitario Doce de Octubre (Spain) Hospital Universitari Vall D'Hebron (Spain) Institut Català d' Oncologia L'Hospitalet (ICO) (Spain) Hospital Provincial de Castellón (Spain) Hospital Universitario Virgen de la Victoria (Spain) Hospital Universitario Virgen del Rocío (Spain) Instituto Valenciano de Oncología (IVO) (Spain) Hospital Clínico Universitario de Valencia (Spain) Hospital del Mar (Spain) Hospital Universitario Sanchinarro-START-CIOCC (Spain)

Dr. Cortes and Dr. Llombart PHERain interview

Beyond Chemotherapy

Dr. Vanes Quiroga

Dr. Sofia Braga

Dr. Silvi Antolín

Dr. Escrivá de Romaní

Dr. Philipp Aftimos

Dr. Manuel Ruiz

Prof. Daniele Generali PHEGain interview

Dr. Jacques Medioni

Dr. Dunca Wheatley